ICAD Highlights Xoft Electronic Brachytherapy System At Key Industry Conference
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced
image analysis, workflow solutions and radiation therapies for the early
identification and treatment of cancer, will highlight its Xoft Axxent
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, will highlight its Xoft Axxent ® eBx™ electronic brachytherapy system at the 2011 Joint American Association of Physicists in Medicine (AAPM)/ Canadian Organization of Medical Physicists (COMP) meeting in Vancouver, British Columbia this weekend. At the show, iCAD will present a poster discussing dosimetry measurements for a new applicator under development for use with the Xoft system. The new interstitial applicator would enable the delivery of Xoft eBx therapy to patients who need very localized radiation delivery, such as those with spinal metastases. Authors will present at the General Poster session on Sunday, July 31 from 3:00 p.m. to 6:00 p.m. in the General Poster Area of Exhibit Hall C. In addition, several clinicians and scientists specializing in radiation therapy and dosimetry will present information on applications for the Axxent eBx system including its use for Intraoperative Radiation Therapy (IORT) and fundamental X-ray source calibration developments at the “Advances in eBx,” Luncheon Symposium at 12:30 p.m. on August 2, in West Wing Rooms 202-204 at the Vancouver Convention Centre. “iCAD has always been committed to innovating in cancer detection, and with our Xoft system we feel that there is a strong opportunity to change the path of treatment for cancer patients, ultimately improving their quality of life,” said Ken Ferry, President and CEO of iCAD. “We are encouraged by the data and look forward to discussions around our Xoft products at this important industry conference.” The Axxent system uses a proprietary isotope-free miniaturized X-ray source to deliver radiation in minimally shielded environments directly to the cancerous tumor bed. The Axxent system is approved for accelerated partial breast irradiation (APBI), which can be delivered twice daily for five days or it can be administered immediately following the lumpectomy procedure in only a few minutes with one course of therapy, also known as Intraoperative Radiation Therapy (IORT). The system is cleared by the U.S. Food and Drug Administration (FDA) for treatment of conditions where radiation is indicated, including early stage breast cancer, skin cancer, and endometrial cancer.